Patents by Inventor Andrzej Steplewski

Andrzej Steplewski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENGINEERED ANTIBODY FOR INHIBITION OF FIBROSIS
    Publication number: 20220185873
    Abstract: A chimeric, humanized or single-chain antibody contains a light chain variable region containing the complementarity determining regions of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and a heavy chain variable region containing the complementarity determining regions SEQ ID NO:5 and SEQ ID NO:6. The antibody or antibody fragment thereof is capable of binding the C-terminal telopeptide of the ?2(I) chain of human collagen I, and is useful in the treatment of diseases or disorders associated with excessive collagen fibril.
    Type: Application
    Filed: December 21, 2021
    Publication date: June 16, 2022
    Inventors: Andrzej Fertala, Andrzej Steplewski
  • Engineered antibody for inhibition of fibrosis
    Patent number: 11208472
    Abstract: A chimeric, humanized or single-chain antibody contains a light chain variable region containing the complementarity determining regions of SEQ ID NO: 1, SEQ ID NO:2 and SEQ ID NO:3, and a heavy chain variable region containing the complementarity determining regions SEQ ID NO:5 and SEQ ID NO:6. The antibody or antibody fragment thereof is capable of binding the C-terminal telopeptide of the ?2(I) chain of human collagen I, and is useful in the treatment of diseases or disorders associated with excessive collagen fibril.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: December 28, 2021
    Assignee: Thomas Jefferson University
    Inventors: Andrzej Fertala, Andrzej Steplewski
  • ENGINEERED ANTIBODY FOR INHIBITION OF FIBROSIS
    Publication number: 20200095308
    Abstract: A chimeric, humanized or single-chain antibody contains a light chain variable region containing the complementarity determining regions of SEQ ID NO: 1, SEQ ID NO:2 and SEQ ID NO:3, and a heavy chain variable region containing the complementarity determining regions SEQ ID NO:5 and SEQ ID NO:6. The antibody or antibody fragment thereof is capable of binding the C-terminal telopeptide of the ?2(I) chain of human collagen I, and is useful in the treatment of diseases or disorders associated with excessive collagen fibril.
    Type: Application
    Filed: December 6, 2019
    Publication date: March 26, 2020
    Inventors: Andrzej Fertala, Andrzej Steplewski
  • ANTIGEN-BINDING DOMAINS OF THE MONOCLONAL ANTI-COLLAGEN I ANTIBODY
    Publication number: 20200048333
    Abstract: An anti-fibrotic biologic comprising, a full-length chimeric IgG variant, a humanized IgG variant, a scFv variant, or other active biologic including the entire CDRs or their fragments able to bind to the ?2Ct target.
    Type: Application
    Filed: October 26, 2017
    Publication date: February 13, 2020
    Inventors: Andrzej FERTALA, Andrzej STEPLEWSKI
  • Engineered antibody for inhibition of fibrosis
    Patent number: 10501533
    Abstract: A chimeric, humanized or single-chain antibody contains a light chain variable region containing the complementarity determining regions of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and a heavy chain variable region containing the complementarity determining regions SEQ ID NO:5 and SEQ ID NO:6. The antibody or antibody fragment thereof is capable of binding the C-terminal telopeptide of the ?2(I) chain of human collagen I, and is useful in the treatment of diseases or disorders associated with excessive collagen fibril.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: December 10, 2019
    Assignee: Thomas Jefferson University
    Inventors: Andrzej Fertala, Andrzej Steplewski
  • ENGINEERED ANTIBODY FOR INHIBITION OF FIBROSIS
    Publication number: 20180072799
    Abstract: A chimeric, humanized or single-chain antibody contains a light chain variable region containing the complementarity determining regions of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and a heavy chain variable region containing the complementarity determining regions SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. The antibody or antibody fragment thereof is capable of binding the C-terminal telopeptide of the ?2(I) chain of human collagen I, and is useful in the treatment of diseases or disorders associated with excessive collagen fibril.
    Type: Application
    Filed: September 8, 2017
    Publication date: March 15, 2018
    Applicant: THOMAS JEFFERSON UNIVERSITY
    Inventors: Andrzej Fertala, Andrzej Steplewski
  • Engineered antibody for inhibition of fibrosis
    Patent number: 9777055
    Abstract: A chimeric, humanized or single-chain antibody contains a light chain variable region containing the complementarity determining regions of SEQ ID NO: 1, SEQ ID NO:2 and SEQ ID NO:3, and a heavy chain variable region containing the complementarity determining regions SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. The antibody or antibody fragment thereof is capable of binding the C-terminal telopeptide of the ?2(I) chain of human collagen I, and is useful in the treatment of diseases or disorders associated with excessive collagen fibril.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: October 3, 2017
    Assignee: Thomas Jefferson University
    Inventors: Andrzej Fertala, Andrzej Steplewski
  • ENGINEERED ANTIBODY FOR INHIBITION OF FIBROSIS
    Publication number: 20150071926
    Abstract: A chimeric, humanized or single-chain antibody contains a light chain variable region containing the complementarity determining regions of SEQ ID NO: 1, SEQ ID NO:2 and SEQ ID NO:3, and a heavy chain variable region containing the complementarity determining regions SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. The antibody or antibody fragment thereof is capable of binding the C-terminal telopeptide of the ?2(I) chain of human collagen I, and is useful in the treatment of diseases or disorders associated with excessive collagen fibril.
    Type: Application
    Filed: February 26, 2013
    Publication date: March 12, 2015
    Inventors: Andrzej Fertala, Andrzej Steplewski
  • Engineered antibody for inhibition of fibrosis
    Patent number: RE49477
    Abstract: A chimeric, humanized or single-chain antibody contains a light chain variable region containing the complementarity determining regions of SEQ ID NO: 1, SEQ ID NO:2 and SEQ ID NO:3, and a heavy chain variable region containing the complementarity determining regions SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. The antibody or antibody fragment thereof is capable of binding the C-terminal telopeptide of the ?2(I) chain of human collagen I, and is useful in the treatment of diseases or disorders associated with excessive collagen fibril.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: March 28, 2023
    Assignee: Thomas Jefferson University
    Inventors: Andrzej Fertala, Andrzej Steplewski